{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-038605","form_type":"8-K","ticker":"OWLT","cik":"0001816708","company_name":"Owlet, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.628811+00:00","generated_at":"2026-06-08T05:22:44.886874+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Owlet Q3 2023 revenue $9.2M, net loss $5.6M; FDA clears Dream Sock OTC","bullets":["Q3 revenue $9.2M, down 47% YoY due to shift to Amazon first-party seller; sell-in shifted to Q4.","Net loss narrowed to $5.6M ($0.84/sh) from $19.4M ($2.42/sh) in Q3 2022.","Gross margin improved to 36.3% from 26.6%; operating expenses cut to $11.2M from $26.4M.","FDA de novo authorization for Dream Sock as first OTC pulse oximeter for healthy infants; launch by Dec 2023.","BabySat monitoring system market introduction began; commercial launch target by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-038605","json":"https://secwatch.observer/filing/0001628280-23-038605.json","markdown":"https://secwatch.observer/filing/0001628280-23-038605.md","text":"https://secwatch.observer/filing/0001628280-23-038605.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816708/000162828023038605/0001628280-23-038605-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816708/000162828023038605/owlt-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:22:44.886874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d374219de495df71ce230c1c421cdd48ea200c9","claim":"Owlet, Inc. reported third quarter ended September 30, 2023 results: revenue $9.2 million, net income $5.6 million, EPS $(0.84).","evidence_excerpt":"Sock® – the first and only over-the-counter, medical grade pulse oximeter classified by FDA for healthy infants and preparing for launch by December 2023. · Achieved revenues of $9.2 million as the Company entered into a new arrangement to start selling products directly to Amazon.com, Inc. under a first-party seller relationship shifting Amazon revenues into Q4. ·","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816708/000162828023038605/0001628280-23-038605-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$9.2 million"},{"label":"Net income","value":"$5.6 million"},{"label":"EPS","value":"$(0.84)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}